

Remarks

Claims 1-27 were pending in U.S. Patent Application 10/348,574 which has been allowed. Applicants kindly request the cancellation of Claims 1-27 and request the acceptance of new Claims 28-43. New Claims 28-43 are directed to thiazolyl compounds. While support for these claims are found throughout the Specification, Table 2 beginning on page 45 and Table 3 beginning on page 50 support and describe thiazolyl containing compounds. Also, the R₁ moiety 2-chlorothiazol-5-yl in Claim 34 is mentioned on page 7, last line of the first paragraph. The heterocycll moiety, thiazolyl, is mentioned on page 7, first paragraph, second sentence. No new matter is being introduced.

The amendment to the Specification updates the priority claim for this new application. No new matter is being added.

Applicant authorizes the Commissioner to charge all fees due to Deposit Account 19-0134. Applicant also requests that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

Thomas Hoxie
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address. Thank you for your assistance with this matter.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7922



David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: February 17, 2004